TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03829657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ampreloxetine
Description: Oral tablet, QD (Daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ampreloxetine
Description: Oral tablet, QD (Daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet, QD
Study: NCT01255644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: 900 mg every 24 hours per os, day 1 through 90
Study: NCT02325284

Intervention type: DEVICE
Intervention: Pressure Algometer Testing
Study: NCT01741675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire and monetary incentive

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire only
Study: NCT01934686

Intervention type: OTHER
Intervention: No treatment given
Description: Patients will fill out a questionnaire by interview.
Study: NCT00116350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 800 mcg sublingual misoprostol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 40 IU Oxytocin IV
Study: NCT00432614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR58611A
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration
Study: NCT02883023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrosclerotherapy
Description: Combination of intralesional bleomycin sclerotherapy and electroporation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional bleomycin injection
Description: Local intralesional injections with bleomycin
Study: NCT02122198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide acetate
Description: Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 9 months. First 6 months under parent study (FAME) protocol (NCT01712230); months 6-9 under sub-study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: Climara transdermal patch 0.075mg/day applied weekly months 6-9

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medroxyprogesterone
Description: Provera 5mg tablets once daily by mouth for 12 days beginning at week 30.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00005039

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-prostate specific antigen vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-prostate specific antigen vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant vaccinia prostate-specific antigen vaccine
Description: Given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant vaccinia prostate-specific antigen vaccine
Description: Given intradermally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04050982

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AF CARE
Description: Patients will receive personalized messages twice weekly that will include behavior recommendations for CVRF reduction and AF education based on the initially entered psychographic profile and data entered.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AF CARE
Description: Patients will receive personalized messages twice weekly that will include behavior recommendations for CVRF reduction and AF education based on the initially entered psychographic profile and data entered.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will be given recommendations for CVRF reduction based on their initial American Heart Association Life Simple 7 (LS7) assessment and will be provided educational materials and be wait listed for digital app 3 months later

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will be given recommendations for CVRF reduction based on their initial American Heart Association Life Simple 7 (LS7) assessment and will be provided educational materials and be wait listed for digital app 3 months later
Study: NCT02170402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octocog alfa (recombinant human coagulation factor VIII)
Description: * Part 1: Pharmacokinetic (PK) analysis - Subset of 24 participants~* Part 2: On-demand treatment regimen~* Part 3: Prophylaxis treatment regimen
Study: NCT02164695

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPCI plus RIPC
Description: All patients will be prepared with an upper-arm blood pressure cuff before arterial puncture (contralateral in case of radial access). In patients allocated into PPCI plus RIPC group, the protocol will be started immediately after cuff preparation. Upper-arm will be exposed to 4 cycles of ischemia/reperfusion, each obtained by 5 min cuff inflation at 200mmHg, followed by 5 min complete deflation.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: PPCI only
Description: All patients randomized to PPCI only arm, the blood pressure cuff will be applied to the arm or the calf but will not be inflated.
Study: NCT03412656

Intervention type: DEVICE
Group type: OTHER
Intervention: SoftHand Pro with CUFF force feedback device
Description: Participants will complete various movement and activity of daily living (ADL) assessments to test the effectiveness of the CUFF device in combination with the Soft Hand Pro (SHP) in conveying haptic force feedback to patients with transradial limb loss, and to assess the extent to which the grip force feedback improves the embodiment of the prosthetic device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SoftHand Pro with CUFF force feedback device
Description: Participants will complete various movement and activity of daily living (ADL) assessments to test the effectiveness of the CUFF device in combination with the Soft Hand Pro (SHP) in conveying haptic force feedback to patients with transradial limb loss, and to assess the extent to which the grip force feedback improves the embodiment of the prosthetic device.
Study: NCT03040375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer counselling
Study: NCT01332357

Intervention type: DRUG
Intervention: Fluticasone propionate/salmeterol combination ED MD
Description: Receipt of fluticasone propionate/salmeterol combination from the ED physician

Intervention type: DRUG
Intervention: Fluticasone propionate/salmeterol combination OP MD
Description: Receipt of fluticasone propionate/salmeterol combination from the OP physician
Study: NCT05904977

Intervention type: PROCEDURE
Intervention: Type B resection or type C resection of the anterior leaf of vesicouterine ligament during the radical hysterectomy (type C)
Description: The patients with cervical cancer who underwent abdominal radical hysterectomy（type C）plus pelvic lymph node dissection by the same surgical team at the Department of Gynecological Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, were included. According to the resection range of the anterior leaf of vesicouterine ligament (VUL), patients were divided into type C resection group (near the bladder wall) and B type resection group (above the ureter).

Intervention type: PROCEDURE
Intervention: Type B resection or type C resection of the anterior leaf of vesicouterine ligament during the radical hysterectomy (type C)
Description: The patients with cervical cancer who underwent abdominal radical hysterectomy（type C）plus pelvic lymph node dissection by the same surgical team at the Department of Gynecological Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, were included. According to the resection range of the anterior leaf of vesicouterine ligament (VUL), patients were divided into type C resection group (near the bladder wall) and B type resection group (above the ureter).
Study: NCT01260012

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Praziquantel+antioxidant suppl
Description: Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonestrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive antioxidant supplement on daily basis for a period of one year.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel + placebo 2mths then antioxidant for 10 mths
Description: Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonestrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for two months which will be followed by antioxidant as a supplement for the rest of the year.

Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: Praziquantel therapy and placebo as supplement
Description: Praziquantel at day 0, 6-weeks and at 12 weeks from start of study. Thereafter praziquantel therapy will be offered if subjects have demonestrable s.mansoni eggs on six-monthly evaluation periods. Placebo will be given as a supplement for one year.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Praziquantel+antioxidant
Description: Praziquantel treatment will be offered at time 0, six weeks and 12 weeks from the start. Antioxidant supplement will be offered on a daily basis for a period of one year
Study: NCT05149898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYN002
Description: CBD Transdermal Gel pharmaceutically manufactured. Cannabidiol (CBD) formulated as a clear gel (transdermal delivery).~Dose received is based on weight.~1. Patients who weigh ≤ 35 kg will receive 125 mg CBD Q12H (every 12 hours); for a total daily dose of 250 mg CBD.~2. Patients who weigh \> 35 kg will receive 250 mg CBD Q12H (±2 hours); for a total daily dose of 500 mg CBD.
Study: NCT01514487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: One single dose of 0.75 mg administered on three different dosing occasions with a 14-day wash-out period between each dosing. Injected subtaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: One single dose of 0.75 mg administered on three different dosing occasions with a 14-day wash-out period between each dosing. Injected subtaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: One single dose of 0.75 mg administered on three different dosing occasions with a 14-day wash-out period between each dosing. Injected subtaneously
Study: NCT03516526

Intervention type: DRUG
Group type: OTHER
Intervention: Natalizumab
Description: Extending dose intervals of natalizumab from 4 weeks to maximum of 8 weeks based on trough natalizumab concentrations
Study: NCT02034942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-sedation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sedation, control
Study: NCT01720342

Intervention type: PROCEDURE
Intervention: Aortic Valve Replacement surgery
Description: Aortic Valve Replacement surgery of the native aortic valve with the Enable® aortic bioprosthesis.
Study: NCT03378986

Intervention type: PROCEDURE
Intervention: Unilateral total hip arthroplasty
Description: Replacement of one hip joint through a mininvasive surgical procedure

Intervention type: PROCEDURE
Intervention: Simultaneous bilateral total hip arthroplasty
Description: Replacement of both hip joints through one-stage mininvasive surgical procedure
Study: NCT01502774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of Cyclosporin
Description: one single intravenous bolus injection of 2.5 mg/Kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One single intravenous bolus injection of Placebo

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Echocardiography
Description: 1 year after AMI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: 1 year after AMI
Study: NCT03388359

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dosimeter ProvoX (Ganshorn)
Description: Device for allergen bronchial challenge test.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eosinophils
Description: Eosinophils are isolated from peripheral blood

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Eosinophils
Description: Eosinophils are isolated from peripheral blood

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Airway smooth muscle cells
Description: Airway smooth muscle cells from healthy subjects (support from the University of Groningen)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Airway smooth muscle cells
Description: Airway smooth muscle cells from healthy subjects (support from the University of Groningen)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibroblasts
Description: Normal human fibroblast cell lines (commercial fibroblast lines)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fibroblasts
Description: Normal human fibroblast cell lines (commercial fibroblast lines)
Study: NCT04203732

Intervention type: PROCEDURE
Intervention: Anesthesia Type
Description: The anesthetic type either general anesthesia or neuraxial anesthesia is the intervention type for patients undergoing primary total joint arthroplasty of the knee or hip.
Study: NCT00822731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy with or without radiotherapy
Description: Treatment regimen will be determined by the sub-type of lymphoma
Study: NCT00933179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gestodene/EE Patch (BAY86-5016)
Description: 21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EE/Levonorgestrel (Microgynon, BAY86-4977)
Description: 21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 3 cycles
Study: NCT04671277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing of breads
Description: During the video recording session, participants were asked to place the whole sample (5-6 g) in the mouth (e.g. single bite) and chew naturally until the bolus is ready for swallowing.~During the second section, participants were asked to place the whole sample in the mouth and chew naturally. After 5 chewing cycles, participants checked all the attributes that describe the texture sensations perceived at the beginning of mastication. A list of attributes and their definitions were provided to guide the participants. Participants proceeded with chewing until the swallowing point when they again checked all the attributes that characterize the texture sensations perceived at the end of mastication. The food bolus was then spat in a container.
Study: NCT03193697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cemented SPII prosthesis
Description: Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-four patients in the control group received a cemented SPII prosthesis (Link, Germany).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cementless Wagner prosthesis
Description: Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-two patients in the trial group received cementless Wagner prosthesis (Zimmer, USA).
Study: NCT00748280

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One-visit root canal therapy
Description: Teeth were isolated, caries was removed and access cavities were prepared. Canal preparation was conducted using step-back technique. The working lengths were determined and confirmed by radiographs. The minimum size file for preparing the working length was size ISO #25 K-file to within 0.5-2 mm of the radiographic apex of the root. During hand instrumentation, canals were frequently irrigated with adequate amount of sterile normal saline solution. The root canals were filled with multiple gutta-percha cones and sealer using lateral condensation technique. Placing a cotton pellet in the pulp chamber, the access cavity was temporarily filled. The treatments of all samples were performed one-visit.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpotomy
Description: Pulpotomy was performed with a large round bur in a high-speed handpiece with copious irrigation; removing inflamed pulp tissue to stump level. Hemostasis was achieved by irrigation of the cavity with sterile normal saline and application of small pieces of sterile cotton pellets. The blood clot-free pulpal wound was covered with approximately 2 mm layer of endodontic bio-materials, a sterile wet cotton pellet was then placed over the MTA/CEM cement and the cavity sealed with Cavit.
Study: NCT01295528

Intervention type: DEVICE
Intervention: Comparison test
Description: Yuyue medical BP meter, accuracy: ±1mmHg and range: 0-300mmHg.
Study: NCT03731650

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maxillary sinus lift
Description: non grafted maxillary sinus floor augmentation with simultaneous implant placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maxillary sinus lift
Description: non grafted maxillary sinus floor augmentation with simultaneous implant placement
Study: NCT01316861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMS Acarbose
Description: EMS Acarbose 50 mg 3 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bayer Acarbose
Description: Bayer Acarbose 50 mg 3 times a day
Study: NCT01810185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose naltrexone
Description: 4.5 mg daily for 12 weeeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03592706

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IKC (Immune Killer Cells)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE (Transcatheter Arterial Chemoembolization)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE (Transcatheter Arterial Chemoembolization)
Study: NCT03688880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAR-CUTIS
Description: MAR-CUTIS was applied in 1 to 2 mm thick layer, ensuring that at least 1 cm of the glue was applied over the length of the wound on each side. The amount of the glue applied was calculated such that one 5-mL syringe covers approximately 8 cm of wound length (giving a total of 10 cm per syringe). For wounds \>8 cm, 2 syringes were required.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabond Advanced
Description: Dermabond Advanced was applied in 1 continuous layer onto a dry wound through painting motions, taking care not to apply adhesive between the wound edges.
Study: NCT01183559

Intervention type: DRUG
Group type: OTHER
Intervention: Vandetanib
Description: Vandetanib 100mg orally escalating to doses of 200 mg daily 7 days a week until completion of radiation therapy

Intervention type: DRUG
Group type: OTHER
Intervention: 5 Fluorouracil (FU)
Description: 5-FU 225 mg/m2/day continuous infusion over96 hours during radiation therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Carboplatin AUC=5 days 1 and 29 during radiation therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Paclitaxel 50 mg/m2 days 1, 8, 15, 22, 29 during radiation therapy

Intervention type: RADIATION
Group type: OTHER
Intervention: External Beam Radiation Therapy (RT)
Description: External Beam Radiation Therapy(XRT)to a total dose of 4,500 centiGray (cGy) (180 cGy fractions daily) Monday through Friday for five weeks
Study: NCT00635037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine and acupuncture
Description: * trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h.~* acupuncture twice a week
Study: NCT04720235

Intervention type: DEVICE
Group type: OTHER
Intervention: Lucira COVID-19 All-In-One test kit
Description: The Lucira COVID-19 All-In-One Test Kit is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19 in nasal swab samples. This test is a single-use test kit that determines whether there is active shedding of the virus which causes COVID-19. This test utilizes a molecular amplification technology for the detection of SARS-CoV-2 RNA.~Positive results are indicative of active infection with SARS-CoV-2. Persons who test positive should self-isolate and seek care from their healthcare provider.~Negative results do not preclude SARS-CoV-2 infection. Persons who continue to experience COVID-like symptoms should seek follow up care from their healthcare provider
Study: NCT03703882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edasalonexent
Description: 100 mg/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04584528

Intervention type: OTHER
Group type: OTHER
Intervention: Electronic Health Record (EHR) Embedded Individualized Pain Plan (IPP)
Description: The IPPs will be developed by the Sickle Cell Disease providers at each study site based on patients' outpatient chronic opioid use and analgesic agent normally required for treatment of VOE in the ED. The Sickle Cell Disease provider will review the IPP with the patient, then upload the IPP to the patient's EHR in a location that will be accessible by the patient and ED provider. Each participating site will train patients and Emergency Department (ED) providers on how to access the IPP in the Electronic Health Record. The following required elements will be included in the EHR-embedded IPP:~* Genotype~* Individual pain plan-preferred analgesic agent, route, dose and dosing interval, last update time~* Name and contact information for the SCD provider~If the enrolled patient has a VOE visit at a nonparticipating ED, the patient will be able to access their IPP via the web or the patient portal app through their EHR. However, data will not be collected from these visits.